Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Psychological Medicine
|
April 5, 2013
Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors
A L Bahorik, C E Newhill, C C Queen, et al.
Psychological Medicine
|
February 14, 2014
Letter to the editor: Critique of Bahorik et al. (2013)--'Underreporting of drug use among individuals with schizophrenia: prevalence and predictors'--a reply
Amber L Bahorik, Christina E Newhill, Courtney C Queen, et al.
Cancer Research
|
January 15, 1991
A recombinant, membrane-acting immunotoxin
A Chovnick, W P Schneider, J Y Tso, et al.
Journal of Pharmaceutics
|
November 12, 2015
Biological Atomic Force Microscopy for Imaging Gold-Labeled Liposomes on Human Coronary Artery Endothelial Cells
Ana-María Zaske, Delia Danila, Michael C Queen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 13, 2001
The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody
N F Landolfi, A B Thakur, H Fu, et al.
International Journal of Cancer
|
June 15, 1994
Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model
R J Kreitman, C N Chang, D V Hudson, et al.
Nature
|
June 1, 1989
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
V K Chaudhary, C Queen, R P Junghans, et al.
The Journal of Experimental Medicine
|
October 1, 1992
Engineered humanized dimeric forms of IgG are more effective antibodies
P C Caron, W Laird, M S Co, et al.
Cancer Research
|
March 1, 1990
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders
R P Junghans, T A Waldmann, N F Landolfi, et al.
Cancer Research
|
December 15, 1992
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies
P C Caron, M S Co, M K Bull, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Psychological Medicine
|
April 5, 2013
Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors
A L Bahorik, C E Newhill, C C Queen, et al.
Psychological Medicine
|
February 14, 2014
Letter to the editor: Critique of Bahorik et al. (2013)--'Underreporting of drug use among individuals with schizophrenia: prevalence and predictors'--a reply
Amber L Bahorik, Christina E Newhill, Courtney C Queen, et al.
Cancer Research
|
January 15, 1991
A recombinant, membrane-acting immunotoxin
A Chovnick, W P Schneider, J Y Tso, et al.
Journal of Pharmaceutics
|
November 12, 2015
Biological Atomic Force Microscopy for Imaging Gold-Labeled Liposomes on Human Coronary Artery Endothelial Cells
Ana-María Zaske, Delia Danila, Michael C Queen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 13, 2001
The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody
N F Landolfi, A B Thakur, H Fu, et al.
International Journal of Cancer
|
June 15, 1994
Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model
R J Kreitman, C N Chang, D V Hudson, et al.
Nature
|
June 1, 1989
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
V K Chaudhary, C Queen, R P Junghans, et al.
The Journal of Experimental Medicine
|
October 1, 1992
Engineered humanized dimeric forms of IgG are more effective antibodies
P C Caron, W Laird, M S Co, et al.
Cancer Research
|
March 1, 1990
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders
R P Junghans, T A Waldmann, N F Landolfi, et al.
Cancer Research
|
December 15, 1992
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies
P C Caron, M S Co, M K Bull, et al.
Page
of 6